Eric Simpson
Oregon Health and Science University · Department of Dermatology, Oregon Health and Science University · OHSU Knight Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Eric Simpson as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:12 UTC. Open this list on ClinicalTrials.gov
- N/ANCT03409367 · A Community-based Assessment of Skin Care, Allergies, and EczemaOregon Health and Science University · completed · Atopic Dermatitis, Atopic Disorders, Eczema · principal investigator
- Ph3NCT03160885 · Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)LEO Pharma · completed · Atopic Dermatitis · principal investigator
- Ph2NCT02525094 · Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic DermatitisMedImmune LLC · completed · Atopic Dermatitis · principal investigator
- N/ANCT01556503 · Sensitivity/Specificity Study of Non-invasive Imaging for Melanoma DiagnosisOHSU Knight Cancer Institute · completed · Melanoma · principal investigator
- N/ANCT01375205 · Comparing Cetaphil Restoraderm System Versus Standard Skin Care in InfantsOregon Health and Science University · completed · Atopic Dermatitis · principal investigator
- N/ANCT01291940 · The Effects of Emollient Therapy on the Skin BarrierOregon Health and Science University · completed · Atopic Dermatitis, Eczema · principal investigator
- Ph2NCT00806221 · An Open-Label Study Investigating the Effects of Early Skin Barrier Protection on the Development of Atopic DermatitisOregon Health and Science University · completed · Atopic Dermatitis · principal investigator
- Ph1/Ph2NCT00723489 · Immune Response to Yellow Fever Vaccination in Adults With Atopic DermatitisNational Institute of Allergy and Infectious Diseases (NIAID) · completed · Atopic Dermatitis · principal investigator
- Ph4NCT00460083 · Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic DermatitisCeragenix Pharmaceuticals · completed · Atopic Dermatitis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:12 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Parent-directed remote identification and severity assessments enabling decentralized trials in atopic dermatitisR01AR082107 · NIAMS · OREGON HEALTH & SCIENCE UNIVERSITY · fiscal years 2024 to 2025 · $302,888 awarded in 2025Same name and institution; not confirmed by an ID
- A Community-based Assessment of Skin Care, Allergies, and Eczema: The CASCADE TrialR01AR071057 · NIAMS · OREGON HEALTH & SCIENCE UNIVERSITY · fiscal years 2018 to 2023 · $300,000 awarded in 2023Grant number is on one of their registry trials
- Planning a Community-Based Trial of Emollients for Atopic Dermatitis PreventionU34AR065739 · NIAMS · OREGON HEALTH & SCIENCE UNIVERSITY · fiscal years 2014 to 2015 · $338,800 awarded in 2015Same name and institution; not confirmed by an ID
- The Role of the Skin Barrier in Atopic Dermatitis Development and PreventionK23AR057486 · NIAMS · OREGON HEALTH & SCIENCE UNIVERSITY · fiscal years 2010 to 2013 · $127,980 awarded in 2013Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:12 UTC. The ranking covers the 200 most relevant of 181 PubMed records, and a shared surname and initials can bring in a namesake. All 181 on PubMed
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.N Engl J Med · 20161,639 citationsRCR 66.2
- Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.N Engl J Med · 20141,130 citationsRCR 38.3
- 991 citationsRCR 44.3
- Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).Br J Dermatol · 2021513 citationsRCR 38.5
- An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study.Lancet Neurol · 2013503 citationsRCR 14.7
- Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention.J Allergy Clin Immunol · 2014488 citationsRCR 19.6
- 476 citationsRCR 19.5
- 476 citationsRCR 33.7
- Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.JAMA Dermatol · 2021426 citationsRCR 32.4
- Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.J Am Acad Dermatol · 2016421 citationsRCR 19.4